US Mulls Capital Gains Tax Cut on Home Sales: Potential...
Key Takeaways A policy proposal to eliminate capital gains tax on US home sales is a significant topic of discussion in 2025, aimed at stimulating the housing market. Current tax...
Key Takeaways A policy proposal to eliminate capital gains tax on US home sales is a significant topic of discussion in 2025, aimed at stimulating the housing market. Current tax...
Key Takeaways The completion of Capital One’s $35.3 billion acquisition of Discover has propelled the combined entity to become the sixth largest bank in the United States by deposits. By...
Key Takeaways Major consumer brands, represented by the Consumer Brands Association, have committed to phasing out synthetic food dyes in response to growing health concerns and regulatory pressure from the...
Key Takeaways Expanse Studios, a subsidiary of Golden Matrix Group (GMGI), has entered a strategic partnership with Bragg Gaming to distribute its portfolio of over 55 games across more than...
Key Takeaways MEI Pharma has allocated $100 million from a private placement to establish a Litecoin (LTC) treasury strategy, becoming the first Nasdaq-listed company to hold LTC as a primary...
Key Takeaways Texas Instruments reported moderate Q1 2025 revenue growth of 3% year-on-year to $3.66 billion, indicating stabilisation but not a strong recovery. Net income and earnings per share (EPS)...
Key Takeaways Enphase Energy reported a double beat for Q2 2025, with both revenue ($359.14 million) and earnings per share ($0.62) surpassing analyst consensus. The company’s stock responded positively, rising...
Key Takeaways A new trade agreement reduces proposed US tariffs on Indonesian goods from 32% to 19%, while eliminating tariffs on US goods entering Indonesia and removing 99% of non-tariff...
Key Takeaways The U.S. will impose a 19% tariff on Indonesian imports, a scaled-back figure from an initially threatened 32%, as part of a strategic trade rebalancing. In return, Indonesia...
Centessa Pharmaceuticals is making waves in the biopharma sphere with a potential 44% upside, targeting a price of $22.00 per share. Their lead candidate, ORX750, aims to tackle narcolepsy and...
CTA Content